26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UCOn 26 July 2024, AbbVie...
Pearce IP BioBlast® for w/e 26 July 2024
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast® for w/e 19 July 2024
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that...
How to Handle Roadblocks with an Australian Patent Examiner
How to Handle Roadblocks with an Australian Patent Examiner
Apple Inc. [2024] APO 25 (25 June 2024)
Amazentis SA [2024] APO 27 (28 June 2024)
Pearce IP BioBlast for w/e 12 July 2024
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's...
Elanco Sheepish as Patent Application Not Inventive
Elanco Australasia Pty Ltd v Abbey Laboratories Pty Ltd [2024] FCA 640
Pearce IP BioBlast for w/e 05 July 2024
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical...
Pearce IP BioBlast for fortnight ending 28 June 2024
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech...
Pearce IP BioBlast for fortnight ending 14 June 2024
14 June 2024 | AU | Approval Alert: Bayer’s High Dose Eylea® (aflibercept) Approved in Australia On 14 June 2024,...
Pearce IP BioBlast w/e 31 May 2024
31 May 2024 | EU | US | Europe’s CHMP Recommends Dupixent® (Dupilumab) as COPD Add-On Treatment On 31 May 2024,...
Carpark Saga Reaches Finale
SARB Management Group Pty Ltd trading as Database Consultants Australia v Vehicle Monitoring Systems Pty Limited (No 2) [2024] FCAFC 53
Pearce IP BioBlast w/e 24 May 2024
24 MAY 2024 | EU | Shanghai Henlius’ & Organon’s Biosimilar Denosumab Applications Validated by EMA On 24 May...
Pearce IP BioBlast w/e 17 May 2024
17 MAY 2024 | KR | New Indication Alert: MSD’s Keytruda® (Pembrolizumab) Approved in Korea for New NSCLC and Cervical...
Navigating Post-Grant Patent Amendments: Lessons from R F Industries v Mine Site Technologies
R F Industries Pty Ltd v Mine Site Technologies Pty Ltd [2024] APO 16 provides a good example of the usefulness of re-examination and opposition to challenge a granted patent.
Pearce IP BioBlast w/e 10 May 2024
10 MAY 2024 | US | Valorum Biologics to Launch Xbrane and Stada’s Ranibizumab Biosimilar in the US On 10 May 2024,...
Pearce IP BioBlast w/e 03 May 2024
03 MAY 2024 | CA | Lupin & Sandoz Launch Rymti® (etanercept) Biosimilar in Canada On 3 May 2024,...
How’s Your Hamstring?
Vald Pty Ltd sued KangaTech Pty Ltd for patent infringement and Kanga cross-claimed alleging that Vald’s patent is invalid on the basis of lack of support, lack of sufficiency and lack of inventive step.